• Explore /
  • Poster
  • / Efficacy and safety of ASK120067 (limertinib) in patients with locally advanced or metastatic EGFR T790M-mutated non–small cell lung cancer: A multicenter, single-arm, phase IIb study.

Efficacy and safety of ASK120067 (limertinib) in patients with locally advanced or metastatic EGFR T790M-mutated non–small cell lung cancer: A multicenter, single-arm, phase IIb study.

Abstract Poster

Authors

null

Baolan Li

Beijing Chest Hospital, Beijing, China

Baolan Li , Lin Wu , Yueyin Pan , Zhijie Pan , Yunpeng Liu , Yun Fan , Yinghua Ji , Jian Fang , Qin Shi , Kai Li , Jianhua Shi , Hongjun Gao , Yanping Hu , Xiang Wang , Zhiyong He , Rui Ma , Yu Zhang , Hongyu Chen , Tingting Song , Yuankai Shi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03502850

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9106)

DOI

10.1200/JCO.2022.40.16_suppl.9106

Abstract #

9106

Poster Bd #

92

Abstract Disclosures

Similar Posters

First Author: Jonathan N. Priantti

First Author: Shiman Wu

First Author: Yuangyuan Zhao

First Author: Suresh S. Ramalingam